What is Akums Drugs & Pharmaceuticals Ltd (AKUMS) share price return in the past 10 years?

Data is not available for this company

What is the share price of Akums Drugs & Pharmaceuticals Ltd (AKUMS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Akums Drugs & Pharmaceuticals Ltd (AKUMS) on 02-Jul-2026 16:59:59 at 16:59 is 637.05.

What is the P/E ratio of Akums Drugs & Pharmaceuticals?

The latest standalone P/E ratio of Akums Drugs & Pharmaceuticals as of 02-Jul-2026 is 89.81.

What is the P/B ratio of Akums Drugs & Pharmaceuticals Ltd (AKUMS)?

The latest standalone P/B ratio of Akums Drugs & Pharmaceuticals Ltd (AKUMS) as of 02-Jul-2026 is 4.13.

What is the 52-week high and low of Akums Drugs & Pharmaceuticals Ltd (AKUMS)?

The 52-week high of Akums Drugs & Pharmaceuticals Ltd (AKUMS) is Rs. 642.20 and the 52-week low is Rs. 410.10.

Akums Drugs & Pharmaceuticals Ltd (AKUMS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Akums Drugs & Pharmaceuticals Ltd (AKUMS)
Brand: Akums Drugs & Pharmaceuticals

Key Metrics

Valuation Multiples

Market Cap

₹10,027 Cr.

Current Price

₹637.1

52-Week Low / High

₹410 / 642

TTM EPS

₹7.1

TTM Sales

₹1,349 Cr.

Book Value per Share

₹154.3

P/E Ratio

89.81

Higher than its 5-year historical median

Industry PE

49.2

Price to Book (P/B)

4.13

Higher than its 5-year historical median

Price to Sales (P/S)

7.43

Higher than its 5-year historical median

EV/EBITDA

44.05

Higher than its 5-year historical median

Dividend Yield

0.47%

Profitability Efficiency

Return on Equity (ROE)

4.72%

Underperforms industry median

Return on Capital Employed (ROCE)

6.67%

Underperforms industry median

Return on Assets (ROA)

4.06%

Operating Profit Margin

7.3%

Net Profit Margin

8.28%

Gross Profit Margin

14.9%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

2.82%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-27.61%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-30.66%

Asset Quality

Promoter Holding

75.26%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹2,397 Cr.

Equity

₹31.5 Cr.

Face Value

₹2

All Time Low / High

₹407.40 / 1174.85

Akums Drugs & Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Akums Drugs & Pharmaceuticals Ltd a good quality company?

Akums Drugs & Pharmaceuticals Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Akums Drugs & Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Akums Drugs & Pharmaceuticals Ltd vs industry peers?

Akums Drugs & Pharmaceuticals Ltd revenue CAGR is 12.22%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Akums Drugs & Pharmaceuticals Ltd?

Promoters hold 75.26% of the Akums Drugs & Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Akums Drugs & Pharmaceuticals Ltd over the last decade?

Over the last 1 year(s), the stock has delivered a CAGR of -7.63% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	6.6%	13.8%	13.7%	9.8%	-29.1%	-73.8%	42.8%	-20.5%	16.7%	6.7%	-
Value Creation Index ⓘ	-0.5	0.0	0.0	-0.3	-3.2	-6.5	2.2	-2.5	0.2	-0.5	-
Growth Parameters ⓘ
Sales ⓘ	628	596	683	737	837	1,162	1,287	1,444	1,312	1,349	1,349
Sales YoY Gr.	-	-5.2%	14.7%	7.9%	13.6%	38.8%	10.7%	12.2%	-9.2%	2.8%	-
Adj EPS ⓘ	2.5	5.2	5.7	3.6	4.4	-2.9	15.4	6.9	10.5	7.6	7.1
YoY Gr.	-	111.3%	9%	-37.8%	23.9%	-166.8%	NA	-55.3%	53.3%	-27.7%	-
BVPS (₹) ⓘ	54.1	59.4	65.1	49.8	39.6	13	21.8	10.1	150.6	158.6	154.3
Adj Net Profit ⓘ	32.1	67.7	73.9	50.8	63	-42.1	220	98.3	161	117	112
Cash Flow from Ops. ⓘ	44.1	71.4	2.8	-21.8	55.6	228	94	248	91	-2.2	-
Debt/CF from Ops. ⓘ	1.3	0.5	18.2	-1.7	0.4	0.5	1.6	0.9	0	-6.3	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8.9%	10%	1.6%	2.8%
Adj EPS ⓘ	13.3%	11.6%	-20.9%	-27.7%
BVPSⓘ	12.7%	32%	93.8%	5.3%
Share Price	-	-	-	9.6%

Key Financial Parameters ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	4.7	9.2	9.2	6.5	9.8	-11.2	88.5	43.2	13.2	4.9	4.5
Op. Profit Mgn % ⓘ	4.7	12.6	12	5.4	9.6	11.4	15.4	16	10.3	7.3	7.2
Net Profit Mgn % ⓘ	5.1	11.4	10.8	6.9	7.5	-3.6	17.1	6.8	12.3	8.6	8.3
Debt to Equity ⓘ	0.1	0	0.1	0.1	0	0.7	0.5	1.6	0	0	0
Working Cap Days ⓘ	346	406	407	458	417	355	404	381	432	372	186
Cash Conv. Cycle ⓘ	102	92	88	93	84	64	61	55	52	53	146

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	628	596	683	737	837	1,162	1,287	1,444	1,312	1,349
Operating Expenses ⓘ +	599	521	601	697	811	1,524	1,089	1,571	1,177	1,251
Manufacturing Costs	52	39	44	66	79	98	107	118	128	133
Material Costs	428	360	418	466	524	768	788	874	801	827
Employee Cost	100	94	103	124	123	136	147	175	202	218
Other Costs ⓘ	19	27	36	41	85	522	46	404	47	73
Operating Profit ⓘ	29	75	82	40	27	-362	198	-127	135	97
Operating Profit Margin (%)	4.7%	12.6%	12.0%	5.4%	3.2%	-31.2%	15.4%	-8.8%	10.3%	7.2%
Other Income ⓘ +	43	55	57	66	55	58	140	94	128	113
Exceptional Items ⓘ	0	0	0	0	-249	0	-145	-19	0	-7
Interest ⓘ	5	3	4	4	1	4	13	18	15	10
Depreciation ⓘ	24	23	23	25	26	28	30	33	40	46
Profit Before Tax ⓘ	43	105	112	76	-195	-335	150	-103	208	148
Tax ⓘ	11	37	37	25	-50	47	25	63	47	37
Profit After Tax	32	68	75	51	-145	-382	125	-165	161	112
PAT Margin (%)	5.2%	11.4%	11.0%	6.9%	-17.4%	-32.9%	9.8%	-11.5%	12.3%	8.3%
Adjusted EPS (₹)	2.5	5.2	5.8	3.6	-10.2	-26.7	8.8	-11.6	10.5	7.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	41.10%

Valuation of Akums Drugs & Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	699	767	842	712	567	186	312	144	2,305	2,428
Share Capital ⓘ	1	1	1	1	1	14	29	29	31	31
Reserves ⓘ	698	766	841	711	566	171	283	115	2,275	2,397
Debt +	47	33	51	36	23	122	142	220	4	14
Long Term Debt	0	0	0	0	0	0	22	16	0	0
Short Term Debt	47	33	51	36	23	122	121	204	4	14
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	43	86	69	108	90	252	178	165	220	201
Others Liabilities ⓘ	71	74	85	570	585	1,254	1,259	1,567	156	170
Total Liabilities ⓘ	860	960	1,046	1,426	1,265	1,814	1,891	2,095	2,685	2,812
Fixed Assets
Net Fixed Assets ⓘ +	227	219	220	226	229	233	253	298	338	407
Gross Block	353	367	389	417	442	470	513	586	675	772
Accumulated Depreciation	126	147	169	191	213	237	260	287	338	365
CWIP ⓘ	0	0	0	1	1	1	16	9	57	52
Investments ⓘ	4	4	4	65	149	141	139	139	366	366
Inventories	88	121	106	123	96	179	197	162	202	230
Trade Receivables	120	121	159	178	212	304	256	234	206	218
Cash Equivalents	3	0	4	72	1	26	9	73	356	771
Others Assets ⓘ	419	494	553	761	576	930	1,020	1,181	1,161	769
Total Assets ⓘ	860	960	1,046	1,426	1,265	1,814	1,891	2,095	2,685	2,812

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	44	71	3	-22	56	228	94	248	91	-2
PBT ⓘ	43	105	112	76	-195	-335	150	-103	208	148
Adjustment ⓘ	-9	-17	-25	-30	284	471	56	344	-57	-37
Changes in Working Capital ⓘ	19	4	-49	-21	-28	100	-82	43	-11	-78
Tax Paid ⓘ	-8	-19	-33	-46	-5	-7	-30	-36	-49	-36
Cash Flow From Investing Activity ⓘ +	-35	-46	-15	-242	-100	-298	-202	-165	-459	-25
Capex	-18	-15	-22	-31	-29	-28	-103	-71	-94	-121
Net Investments	0	0	0	-57	38	24	-0	0	-275	-406
Others ⓘ	-17	-31	7	-153	-109	-293	-98	-95	-90	502
Cash Flow From Financing Activity ⓘ +	-8	-28	15	302	3	95	90	-21	375	-3
Net Proceeds from Shares ⓘ	0	0	0	320	0	0	0	0	637	0
Net Proceeds from Borrowing ⓘ	-12	0	0	0	0	0	25	-3	-22	0
Interest Paid ⓘ	-5	-2	-2	-2	-1	-2	-11	-18	-15	-10
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	9	-25	18	-16	3	97	76	1	-225	7
Net Cash Flow ⓘ	1	-2	3	38	-42	25	-18	62	8	-30

Financial Ratio

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	4.75	9.24	9.3	6.54	-22.73	-101.46	50.47	-72.66	13.15	4.72
ROCE (%)	6.57	13.83	13.69	9.77	-29.06	-73.83	42.75	-20.46	16.66	6.67
Asset Turnover Ratio	0.74	0.66	0.68	0.6	0.62	0.75	0.69	0.72	0.55	0.49
PAT to CFO Conversion(x)	1.38	1.04	0.04	-0.43	N/A	N/A	0.75	N/A	0.57	-0.02
Working Capital Days
Receivable Days	67.90	73.50	74.80	83.40	84.90	81	79.40	61.90	61.20	57.30
Inventory Days	60	64	60.80	56.80	47.70	43.20	53.40	45.40	50.60	58.40
Payable Days	36	65.40	67.40	69.30	69.10	81.30	99.60	71.60	87.60	92.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Akums Drugs & Pharmaceuticals Ltd FAQs

The current trading price of Akums Drugs & Pharma on 02-Jul-2026 16:59 is ₹637.0.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jul-2026 the market cap of Akums Drugs & Pharma stood at ₹10,026.8 Cr

The latest P/E ratio of Akums Drugs & Pharma as of 01-Jul-2026 is 89.81.

The latest P/B ratio of Akums Drugs & Pharma as of 01-Jul-2026 is 4.13.

The 52-week high of Akums Drugs & Pharma is ₹642.2 and the 52-week low is ₹410.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Akums Drugs & Pharma is ₹1,349 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Akums Drugs & Pharmaceuticals Ltd is a average quality company.

The key valuation ratios of Akums Drugs & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Akums Drugs & Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Akums Drugs & Pharmaceuticals Ltd

The company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of ‘Akums Drugs and Pharmaceuticals Limited’, pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi (RoC). The company received a certificate of commencement of business issued by the RoC dated May 13, 2004.

Established in 2004, Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, the company owns the intellectual property for the manufacturing processes of several of its formulations, and its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Some of its other services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to its core CDMO business, it is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).

Business area of the company

As a CDMO, the company produces an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. It also engages in the marketing of trade generic and products under its own brand through distributors and alternative channels across India.

Key Awards and accreditations

2018: Received India Pharma Leader Award by Government of India.
2019: Received India Pharma Leader Award by Government of India.
2021: Award for India Pharma Award for Excellence in Contract Research and Manufacturing by Informamarkets.
2022: Award for Excellence in R&D and Innovation by ET Ascent.
2022: Awarded the International Healthcare award as Pharmaceutical Company of the Year in contract manufacturing by Times Cyber Media.
2022: Awarded the Excellence in Operations – Manufacturing by CPHI Awards.
2022: Awarded Asia’s Pharma Excellence Awards in Innovation in Nutraceutical, Cosmetic and Wellness Award by CMO Asia.
2023: Awarded Dream Employer of the Year by Times Ascent.
2023: Awarded the Excellence Award in Nutraceutical category by IHW Council.
2023: Award for the best brand based in North India by Exchange4Media.
2023: Awarded the best Technology Adaption – Cash Management Services by HDFC Bank.
2023: Awarded 2nd Runner up in Best Trademarks portfolio by CII Industrial Intellectual Property Awards.
2023: Awarded the Excellence in Formulations by India Pharma World Awards, The Economic Times.
2023: Awarded the Most Admired Quality Pharmaceutical Manufacturer of India 2023 by Observe Now.
2023: Awarded the Certificate of Appreciation for Excellence in Innovative Formulations – Nutraceutical and Wellness Award by Food Safety and Nutrition Summit and Awards 2023.

Major events and milestones

2004: Incorporation of the company.
2004: Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand.
2007: Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand.
2009: Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals.
2010: Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
2010: Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
2010: Incorporated Akumentis Healthcare Limited to venture into branded formulations.
2011: Innovated bi-layered sustained release tablets for the first time.
2012: Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities.
2013: Innovated tablet-in-tablet sustained release tablets for the first time.
2013: Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities.
2013: Expanded into the African market.
2015: Expanded into the Asian market.
2015: Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market.
2016: Maxcure Nutravedics Limited received US-NSF certification.
2019: Investment by Ruby QC Investment Holdings Pte. Ltd. in the company to become a minority shareholder.
2021: Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs.
2021: Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited.
2022: Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets.
2022: Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
2023: Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
2023: Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Akums Drugs & Pharmaceuticals Ltd (AKUMS)

Akums Drugs & Pharmaceuticals Ltd (AKUMS)

Akums Drugs & Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Akums Drugs & Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Akums Drugs & Pharmaceuticals Ltd FAQs

What is the share price of Akums Drugs & Pharma?

What is the market cap of Akums Drugs & Pharma?

What is the P/E ratio of Akums Drugs & Pharma?

What is the P/B ratio of Akums Drugs & Pharma?

What is the 52-week high and low of Akums Drugs & Pharma?

What is the TTM revenue of Akums Drugs & Pharma?

Is Akums Drugs & Pharmaceuticals Ltd a good quality company?

Is Akums Drugs & Pharmaceuticals Ltd undervalued or overvalued?

Is Akums Drugs & Pharmaceuticals Ltd a good buy now?

About Akums Drugs & Pharmaceuticals Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.